• A BridgeBio Pharma drug developed for dwarfism increased children’s growth rates in a pivotal clinical trial,meeting the study’s main goaland boosting the daily pill’s chances to offer an alternative to chronic injections used to treat the condition. • The BridgeBio drug, infigratinib, was tested in a placebo-controlled Phase 3 study that enrolled 113 children age 3 to 18 who have achondroplasia, the most common form of dwarfism. • Preliminary data reported Thursday show that daily doses of the study drug led to an average 2.1 cm increase in annualized height velocity from baseline, measured at one year and compared to placebo. • The absolute change in height was an average 1.74 cm compared to placebo at one year. • Achondroplasia can also affect body proportionality. • BridgeBio reported infigratinib met a key secondary goal achieving statistically significant improvement in proportionality compared to placebo in children younger than 8 years old.
Article Summaries:
- A BridgeBio Pharma drug developed for dwarfism increased children’s growth rates in a pivotal clinical trial, meeting the study’s main goal and boosting the daily pill’s chances to offer an alternative to chronic injections used to treat the condition. The BridgeBio drug, infigratinib, was tested in a placebo-controlled Phase 3 study that enrolled 113 children age 3 to 18 who have achondroplasia, the most common form of dwarfism. Preliminary data reported Thursday show that daily doses of the study drug led to an average 2.1 cm increase in annualized height velocity from baseline, measured at
Sources: